HU226617B1 - Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, and pharmaceutical composition containing the compound as active ingredient - Google Patents

Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, and pharmaceutical composition containing the compound as active ingredient Download PDF

Info

Publication number
HU226617B1
HU226617B1 HU9802897A HUP9802897A HU226617B1 HU 226617 B1 HU226617 B1 HU 226617B1 HU 9802897 A HU9802897 A HU 9802897A HU P9802897 A HUP9802897 A HU P9802897A HU 226617 B1 HU226617 B1 HU 226617B1
Authority
HU
Hungary
Prior art keywords
pyridyl
oxadiazine
piperidinyl
dihydro
methyl
Prior art date
Application number
HU9802897A
Other languages
English (en)
Hungarian (hu)
Inventor
Andrea Jednakovits
Laszlo Dr Ueroegdi
Laszlo Dr Denes
Istvan Dr Kurucz
Mihaly Barabas
Ernoe Dr Bacsy
Zsuzsanna Korom
Ede Dr Marvanyos
Zoltan Dr Nagy
Laszlo Dr Uerge
Karoly Acsai
Jenoe Dr Szilbereky
Zita Csakai
Peter Dr Krajcsi
Magdolna Toeroek
Original Assignee
Cytrx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytrx Corp filed Critical Cytrx Corp
Priority to HU9802897A priority Critical patent/HU226617B1/hu
Publication of HU9802897D0 publication Critical patent/HU9802897D0/hu
Priority to UA2001063850A priority patent/UA70340C2/uk
Priority to JP2000588174A priority patent/JP2002532498A/ja
Priority to KR1020017002870A priority patent/KR100661774B1/ko
Priority to AU17906/00A priority patent/AU765336B2/en
Priority to AT99961225T priority patent/ATE266027T1/de
Priority to US09/762,949 priority patent/US6384029B1/en
Priority to DK99961225T priority patent/DK1147105T3/da
Priority to ES99961225T priority patent/ES2219091T3/es
Priority to PT99961225T priority patent/PT1147105E/pt
Priority to DE69917074T priority patent/DE69917074T2/de
Priority to CZ20011550A priority patent/CZ300764B6/cs
Priority to PCT/HU1999/000095 priority patent/WO2000035914A1/en
Priority to BR9913982-0A priority patent/BR9913982A/pt
Priority to HR20010133A priority patent/HRP20010133B1/xx
Priority to EP99961225A priority patent/EP1147105B1/en
Priority to IL14151599A priority patent/IL141515A/xx
Priority to SI9930566T priority patent/SI1147105T1/xx
Priority to EEP200100188A priority patent/EE04551B1/xx
Priority to RU2001118854/04A priority patent/RU2222538C2/ru
Priority to SK234-2001A priority patent/SK285582B6/sk
Priority to YUP-250/01A priority patent/RS50129B/sr
Priority to PL346767A priority patent/PL196584B1/pl
Priority to CA002340734A priority patent/CA2340734C/en
Publication of HUP9802897A2 publication Critical patent/HUP9802897A2/hu
Priority to ZA200101182A priority patent/ZA200101182B/en
Priority to BG105342A priority patent/BG65179B1/bg
Priority to NO20012310A priority patent/NO317649B1/no
Publication of HUP9802897A3 publication Critical patent/HUP9802897A3/hu
Publication of HU226617B1 publication Critical patent/HU226617B1/hu
Priority to JP2011128516A priority patent/JP5620340B2/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HU9802897A 1998-12-14 1998-12-14 Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, and pharmaceutical composition containing the compound as active ingredient HU226617B1 (en)

Priority Applications (28)

Application Number Priority Date Filing Date Title
HU9802897A HU226617B1 (en) 1998-12-14 1998-12-14 Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, and pharmaceutical composition containing the compound as active ingredient
UA2001063850A UA70340C2 (en) 1998-12-14 1999-07-12 Optically active 5,6-dihydro-5-[(1-piperidinyl)-meoptically active 5,6-dihydro-5-[(1-piperidinyl)-methyl-3-(3-pyridyl)-4h-1,2,4-oxadiazine, a method fthyl-3-(3-pyridyl)-4h-1,2,4-oxadiazine, a method for the treatment and prevention of vascular diseasor the treatment and prevention of vascular diseases and a pharmaceutical composition es and a pharmaceutical composition
CA002340734A CA2340734C (en) 1998-12-14 1999-12-07 Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
HR20010133A HRP20010133B1 (en) 1998-12-14 1999-12-07 Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
SI9930566T SI1147105T1 (en) 1998-12-14 1999-12-07 Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatement of vascular diseases
AU17906/00A AU765336B2 (en) 1998-12-14 1999-12-07 Optically active pyridyl-4H-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
AT99961225T ATE266027T1 (de) 1998-12-14 1999-12-07 Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten
US09/762,949 US6384029B1 (en) 1998-12-14 1999-12-07 Optically active pyridyl-4h-1,2,4-oxdadiazine derivative and its use in the treatment of vascular diseases
DK99961225T DK1147105T3 (da) 1998-12-14 1999-12-07 Optisk aktivt pyridyl-4H-1,2,4-oxadiazinderivat og anvendelse af dette til behandling af karsygdomme
ES99961225T ES2219091T3 (es) 1998-12-14 1999-12-07 Derivado de piridil-4h-1,2,4-oxadiazina optimamente activo y su uso en el tratamiento de las enfermedades vasculares.
PT99961225T PT1147105E (pt) 1998-12-14 1999-12-07 Derivado de piridil-4h-1,2,4-oxadiazina opticamente activo e sua utilizacao no tratamento de doencas vasculares
DE69917074T DE69917074T2 (de) 1998-12-14 1999-12-07 Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten
CZ20011550A CZ300764B6 (cs) 1998-12-14 1999-12-07 Opticky aktivní derivát pyridyl-4H-1,2,4-oxadiazinu, jeho použití pri lécbe vaskulárních onemocnení a farmaceutické kompozice ho obsahující
PCT/HU1999/000095 WO2000035914A1 (en) 1998-12-14 1999-12-07 Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
BR9913982-0A BR9913982A (pt) 1998-12-14 1999-12-07 Derivado de piridil-4h-1,2,4-oxadiazina opticamente ativo e seu uso no tratamento de doenças vasculares
JP2000588174A JP2002532498A (ja) 1998-12-14 1999-12-07 光学活性ピリジル−4h−1,2,4−オキサジアジン誘導体およびその血管疾患の治療における使用
EP99961225A EP1147105B1 (en) 1998-12-14 1999-12-07 Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatement of vascular diseases
IL14151599A IL141515A (en) 1998-12-14 1999-12-07 Optically active pyridyl- 4h - 1, 2, 4 - oxadiazine derivative and its use in the treatment of vascular diseases and pharmaceutical composition comprising same
KR1020017002870A KR100661774B1 (ko) 1998-12-14 1999-12-07 광학적 활성 피리딜-4에이치-1,2,4-옥사디아진 유도체 및이것의 혈관 질환의 치료에서의 용도
EEP200100188A EE04551B1 (et) 1998-12-14 1999-12-07 Optiliselt aktiivne pridl-4H-1,2,4-oksadiasiini derivaat ja selle kasutamine vaskulaarsete haiguste ravis
RU2001118854/04A RU2222538C2 (ru) 1998-12-14 1999-12-07 Оптически активное производное пиридил-4н-1,2,4-оксадиазина и фармацевтическая композиция
SK234-2001A SK285582B6 (sk) 1998-12-14 1999-12-07 Opticky aktívny derivát pyridyl-4H-1,2,4-oxadiazínu a jeho použitie na výrobu liečiva na liečenie vaskulárnych ochorení
YUP-250/01A RS50129B (sr) 1998-12-14 1999-12-07 Optički aktivan derivat piridil-4h-1,2,4-oksadiazina i njegova upotreba u proizvodnji lekova za tretiranje vaskularnih bolesti
PL346767A PL196584B1 (pl) 1998-12-14 1999-12-07 Optycznie czynna pochodna pirydylo-4H-1,2,4-oksadiazyny i jej zastosowanie w leczeniu chorób naczyń
ZA200101182A ZA200101182B (en) 1998-12-14 2001-02-12 Optically active pyridyl-4H-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases.
BG105342A BG65179B1 (bg) 1998-12-14 2001-03-14 Оптичноактивно производно на пиридил-4н-1,2,4-оксадиазин и приложението му за производство на медикаменти за лечение на съдови заболявания
NO20012310A NO317649B1 (no) 1998-12-14 2001-05-10 Optisk aktiv pyridyl-4H-1,2,4-oksazdiazinderivat og dets anvendelse ved behandling av karsykdommer
JP2011128516A JP5620340B2 (ja) 1998-12-14 2011-06-08 光学活性ピリジル−4h−1,2,4−オキサジアジン誘導体およびその血管疾患の治療における使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU9802897A HU226617B1 (en) 1998-12-14 1998-12-14 Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, and pharmaceutical composition containing the compound as active ingredient

Publications (4)

Publication Number Publication Date
HU9802897D0 HU9802897D0 (en) 1999-02-01
HUP9802897A2 HUP9802897A2 (hu) 2000-11-28
HUP9802897A3 HUP9802897A3 (en) 2001-08-28
HU226617B1 true HU226617B1 (en) 2009-04-28

Family

ID=10991166

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9802897A HU226617B1 (en) 1998-12-14 1998-12-14 Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, and pharmaceutical composition containing the compound as active ingredient

Country Status (27)

Country Link
US (1) US6384029B1 (cg-RX-API-DMAC7.html)
EP (1) EP1147105B1 (cg-RX-API-DMAC7.html)
JP (2) JP2002532498A (cg-RX-API-DMAC7.html)
KR (1) KR100661774B1 (cg-RX-API-DMAC7.html)
AT (1) ATE266027T1 (cg-RX-API-DMAC7.html)
AU (1) AU765336B2 (cg-RX-API-DMAC7.html)
BG (1) BG65179B1 (cg-RX-API-DMAC7.html)
BR (1) BR9913982A (cg-RX-API-DMAC7.html)
CA (1) CA2340734C (cg-RX-API-DMAC7.html)
CZ (1) CZ300764B6 (cg-RX-API-DMAC7.html)
DE (1) DE69917074T2 (cg-RX-API-DMAC7.html)
DK (1) DK1147105T3 (cg-RX-API-DMAC7.html)
EE (1) EE04551B1 (cg-RX-API-DMAC7.html)
ES (1) ES2219091T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20010133B1 (cg-RX-API-DMAC7.html)
HU (1) HU226617B1 (cg-RX-API-DMAC7.html)
IL (1) IL141515A (cg-RX-API-DMAC7.html)
NO (1) NO317649B1 (cg-RX-API-DMAC7.html)
PL (1) PL196584B1 (cg-RX-API-DMAC7.html)
PT (1) PT1147105E (cg-RX-API-DMAC7.html)
RS (1) RS50129B (cg-RX-API-DMAC7.html)
RU (1) RU2222538C2 (cg-RX-API-DMAC7.html)
SI (1) SI1147105T1 (cg-RX-API-DMAC7.html)
SK (1) SK285582B6 (cg-RX-API-DMAC7.html)
UA (1) UA70340C2 (cg-RX-API-DMAC7.html)
WO (1) WO2000035914A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200101182B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013045962A1 (en) 2011-09-26 2013-04-04 Hazay Balazs Pharmaceutical composition for the prevention and/or treatment of muscle atrophy

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057664A1 (en) 2002-01-11 2003-07-17 Biorex Kutató És Fejlesztö Rt. Carboxamidine derivatives and their use in the treatment of vascular diseases
KR100678577B1 (ko) * 2006-09-11 2007-02-06 조만규 가정용 분전함
JP5616336B2 (ja) 2008-06-26 2014-10-29 オルファザイム エーピーエスOrphazyme Aps 酵素活性の調節因子としてのHsp70の使用
KR20110084514A (ko) 2008-11-18 2011-07-25 산텐 세이야꾸 가부시키가이샤 피리딘-3-카르발데히드 o-(피페리딘-1-일-프로필)-옥심 유도체를 유효 성분으로서 함유하는 망맥락막 변성 질환의 치료제
US9662375B2 (en) 2010-11-30 2017-05-30 Orphazyme Aps Methods for increasing intracellular activity of Hsp70
US10709700B2 (en) 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
WO2017178029A1 (en) 2016-04-13 2017-10-19 Orphazyme Aps Heat shock proteins and cholesterol homeostasis
ES2831764T3 (es) 2016-04-29 2021-06-09 Orphazyme As Arimoclomol para el tratamiento de trastornos asociados a glucocerebrosidasa
WO2018215597A1 (en) 2017-05-24 2018-11-29 Orphazyme A/S Heat shock protein inducers and frontotemporal disorders
MX2020012480A (es) 2018-05-28 2021-03-25 Orphazyme As Niveles de la proteina de choque termico 70 (hsp70) en las muestras de celulas mononucleares de la sangre periferica (pbmc) como biomarcador para enfermedades.
EP4247792A1 (en) 2020-11-19 2023-09-27 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT395853B (de) * 1991-01-31 1993-03-25 Chem Pharm Forsch Gmbh Neue imidazolderivate, verfahren zu ihrer herstellung und ihre verwendung
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
DE69628320D1 (de) * 1995-11-03 2003-06-26 Summit Packaging Systems Ltd Vorrichtung zum abgeben und füllen von beuteln an einem kassenplatz eines supermarkts
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013045962A1 (en) 2011-09-26 2013-04-04 Hazay Balazs Pharmaceutical composition for the prevention and/or treatment of muscle atrophy

Also Published As

Publication number Publication date
IL141515A0 (en) 2002-03-10
RS50129B (sr) 2009-03-25
EE200100188A (et) 2002-08-15
DE69917074T2 (de) 2005-05-12
DE69917074D1 (de) 2004-06-09
SK2342001A3 (en) 2001-08-06
WO2000035914A1 (en) 2000-06-22
PL196584B1 (pl) 2008-01-31
US6384029B1 (en) 2002-05-07
BG105342A (en) 2001-12-29
EE04551B1 (et) 2005-10-17
ES2219091T3 (es) 2004-11-16
HRP20010133B1 (en) 2005-02-28
CZ300764B6 (cs) 2009-08-05
HU9802897D0 (en) 1999-02-01
HUP9802897A3 (en) 2001-08-28
CA2340734C (en) 2008-10-21
BR9913982A (pt) 2001-06-12
AU765336B2 (en) 2003-09-18
JP2011201916A (ja) 2011-10-13
YU25001A (sh) 2004-07-15
PT1147105E (pt) 2004-07-30
KR100661774B1 (ko) 2006-12-28
ZA200101182B (en) 2002-02-12
RU2222538C2 (ru) 2004-01-27
SI1147105T1 (en) 2004-08-31
JP5620340B2 (ja) 2014-11-05
JP2002532498A (ja) 2002-10-02
HRP20010133A2 (en) 2002-02-28
BG65179B1 (bg) 2007-05-31
DK1147105T3 (da) 2004-06-01
CZ20011550A3 (cs) 2001-08-15
SK285582B6 (sk) 2007-04-05
CA2340734A1 (en) 2000-06-22
PL346767A1 (en) 2002-02-25
IL141515A (en) 2005-09-25
AU1790600A (en) 2000-07-03
ATE266027T1 (de) 2004-05-15
KR20010073129A (ko) 2001-07-31
UA70340C2 (en) 2004-10-15
NO20012310L (no) 2001-05-10
NO317649B1 (no) 2004-11-29
EP1147105A1 (en) 2001-10-24
NO20012310D0 (no) 2001-05-10
HUP9802897A2 (hu) 2000-11-28
EP1147105B1 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
JP5620340B2 (ja) 光学活性ピリジル−4h−1,2,4−オキサジアジン誘導体およびその血管疾患の治療における使用
JP4316794B2 (ja) イソキノリン誘導体及び医薬
JP2011201916A5 (cg-RX-API-DMAC7.html)
JPWO1999020620A1 (ja) イソキノリン誘導体及び医薬
JP3815691B2 (ja) プロペン酸誘導体
WO1997028130A1 (en) Isoquinoline derivatives and drugs
MC1491A1 (fr) Nouveaux composes bicycliques,procedes pour les preparer et formules pharmaceutiques contenant ces composes
BR112012007828B1 (pt) compostos inibidores da xantina oxidase, processo para preparar os compostos, e, composição farmacêutica para a inibição da xantina oxidase
EP0112191B1 (fr) Nouveaux dérivés du 4-(1H-indol-3-yl) alpha-méthylpipéridine 1-éthanol, leurs sels, le procédé de préparation, l'application à titre de médicaments et les compositions les renfermant
US4990509A (en) Sulfonamide anti-arrhythmic agents
EA004539B1 (ru) Комбинационная терапия для лечения резистентной депрессии
RU2130019C1 (ru) Производные 3(2н)-пиридазинона, фармацевтическая композиция, способ лечения
US7361655B2 (en) Pharmaceutically effective compounds
TW200523259A (en) Amidomethyl-substituierte 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2h-chromen-6-ylderivate, verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
WO2016206576A1 (zh) 一种氘代噻吩并哌啶衍生物、制备方法及其应用
JPH033671B2 (cg-RX-API-DMAC7.html)
HU196069B (en) Process for production of 8-/dihydropiridil-carbamoiloxi-methil/-ergolines and medical compounds containing these compositions
CN112759560B (zh) 含有n-氨基哌嗪片段的苯并噻嗪-4-酮类化合物及其制备方法
JPH02135A (ja) 多還式化合物とこれを含有する医薬組成物
KR910004674B1 (ko) 부정맥치료제
HU226206B1 (en) Optically active piperidinoalkyl-4h-1,2,4-oxadiazine derivative, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
HU201026B (en) Bicyclic compounds.
JP2001114699A (ja) キマーゼ阻害作用を有する化合物を有効成分とする血管新生阻害剤
JPH11228412A (ja) 心筋選択的カルシウム拮抗薬
ZA200404996B (en) Carboxamidine derivatives and their use in the treatment of vascular diseases

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: CYTRX CORPORATION, US

Free format text: FORMER OWNER(S): BIOREX KUTATO ES FEJLESZTOE RT., HU

MM4A Lapse of definitive patent protection due to non-payment of fees